ADELAIDE, Australia / RankWire.AI / – Researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have uncovered a novel molecular switch responsible for promoting the spread of aggressive tumors. Their findings, published in EMBO Molecular Medicine, reveal that Australian scientists have identified a promising new approach to fight triple-negative breast cancer by restoring a crucial regulatory molecule called miR-342. This breakthrough could lead to new strategies for preventing life-threatening secondary cancers in organs like the lungs and bones.
Although triple-negative breast cancer makes up 10% to 15% of Australia’s roughly 21,000 annual breast cancer diagnoses, it is responsible for a disproportionately high number of fatalities. This particular subtype lacks estrogen, progesterone, and HER2 receptors, which means that standard targeted hormone therapies are ineffective. The lead researchers demonstrated that when miR-342 levels drop, it causes an overactivation of the E2F pathway—a cancer-promoting mechanism—thereby enabling dormant cancer cells to disseminate throughout the body and develop into dangerous secondary tumors.
Potential for Diagnostic Biomarker Testing to Identify Patients Who Would Benefit Most
In pre-clinical experiments, scientists showed that increasing miR-342 levels significantly decreased the spread of cancer cells to distant organs. Moreover, they found that palbociclib, an existing CDK4/6 inhibitor drug already approved for hormone receptor-positive breast cancers, markedly slowed metastatic tumor growth in models with low miR-342 levels. These results suggest that measuring miR-342 levels could enable clinicians to repurpose existing drugs to treat patients with high metastatic risk more effectively.
Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology, who is a co-senior author, stated that the greatest challenge in treating aggressive breast cancers is preventing metastasis. Gregory emphasized that because palbociclib targets the overactive E2F pathway, administering the medication after cancer cells have already spread can prevent microscopic deposits from enlarging. Instead of solely aiming to shrink primary tumors, this approach halts the progression of microscopic secondary cancers into life-threatening conditions.
miR-342 as a Master Regulator for Critical Cancer Genes
The research team pointed out that the biological diversity of triple-negative breast cancer has historically impeded the development of universal targeted therapies. By identifying a specific biological weakness common to a particular subgroup of patients, their study paves the way for more personalized treatment strategies. As Australian scientists continue to explore this promising method of combating triple-negative breast cancer, efforts are underway to validate the findings using patient-derived models prior to initiating clinical trials.
The discovery has been widely welcomed by medical oncologists and cancer research organizations across Australia, who acknowledge the pressing need for expanded treatment options, especially when primary therapies do not succeed. The research team plans to collaborate with international clinical networks to expedite the development of biomarker screening protocols. Confirming the efficacy of miR-342 testing could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor therapies early in the treatment process, potentially improving outcomes for high-risk patients.